ELEVATE Data Raise PureTech’s IPF Prospects

The company’s deupirfenidone, a selectively deuterated version of Roche's Esbriet, has bested the original in a Phase IIb trial in idiopathic pulmonary fibrosis patients. Now, PureTech can finalize the Phase III program and decide how to finance it.